Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants With Advanced Solid Tumors
Latest Information Update: 16 Jun 2025
At a glance
- Drugs RP-1664 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms LIONS
Most Recent Events
- 10 Jun 2025 Planned End Date changed from 1 Jan 2027 to 1 Oct 2025.
- 10 Jun 2025 Planned primary completion date changed from 1 Jan 2027 to 1 Sep 2025.
- 08 May 2025 Status changed from recruiting to active, no longer recruiting.